InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: dia76ca post# 141037

Monday, 09/16/2013 11:39:08 PM

Monday, September 16, 2013 11:39:08 PM

Post# of 345858
Allergan is known for its specialty in eye care and Peregrines pipeline could help them out, in addition to expanding into other oncology areas where they are not well known at all.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91787866&txt2find=allergan
------------------------------------------------------------------

One of the concerns though is right after Peregrine announced the passing of Dr. Philip Thorpe, there was the patent agent "Brigitte Phan" on the top of his PAV list so I still say she

1) was working with Dr. Thorpe / Peregrine on some patents ... but that doesn't make sense because she is at Allergan... or

2) She knew of his patents or pending patents and were asked to review them possibly? The entire anti-PS platform patent portfolio is soo broad and the first thing "ANY" company will do to verify this is check with a patent attorney to review the existing patents to see if there are any loop holes...etc ... for other MOA for other drugs..etc ? just my guess

Now that alone didn't make me think of anything much ... till that first time seeing "Lisa Ortega" on that list with Gerald Finken and Jeanette Bleecker -- >> Lisa Ortega is at Allergan as well

To top all that off... we have Luhrs and Parseghian leaving Peregrine and landing at Allergan.

..just too many coincidences there all wrapped up into one.

Remember... I'm not saying any of these names I toss out have an agenda-- but there is a solid connection. Check every name on this list... its where it all started: Lisa Ortega at the very top works for Allergan and job title: CSM Planning & Systems Manager ... now check every name below hers (of course we have Finken and Bleecker) but every name is a CSM employee. The connection certainly seems to go back and forth with BMS / CSM / Allergan ... thats where the Federal Authorities should have an aswer at some point.

http://mygcsg.com/community/members/?s=CSM

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News